Business
Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer
Dr Steineger’s appointment will be effective from September 1. She brings extensive experience as a biotech executive, with a proven track record spanning financial analysis, venture capital, and business development. Damian Marron, current ...
About this update from Cantargia Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"Dr Steineger’s appointment will be effective from September 1.","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"She brings extensive experience as a biotech executive, with a proven track record spanning financial analysis, venture capital, and business development.","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"Damian Marron, current Interim CEO, will continue as a member of the Cantargia Board.","length":85,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":311,"olType":false},{"type":"text","content":"LUND, SWEDEN / ACCESS Newswire / August 18, 2025 / Cantargia (STO:CANTA) today announced that it has appointed the highly experienced biotechnology executive and two-time CEO, Dr Hilde Steineger, as its new Chief Executive Officer. Hilde will be joining Cantargia from NorthSea Therapeutics (NorthSea), where she has been Co-Founder and the Chief Operating Officer since 2017, as well as the CEO of Staten Biotechnology, since 2017, where she led a $480M deal with Novo Nordisk.","length":478,"tagName":"p"},{"type":"text","content":""I am thrilled to join Cantargia at this exciting stage of its development. The company's focus on innovative antibody-based therapies targeting IL1RAP and its strategic partnership with Otsuka represent significant opportunities to advance impactful treatments. I look forward to contributing to Cantargia's ongoing success and working with the team to create value for all stakeholders," says Hilde Steineger.","length":429,"tagName":"p"},{"type":"text","content":""We welcome Dr Hilde Steineger as our new CEO. Her appointment is a natural development for Cantargia as a maturing company with two product candidates in clinical trials and having recently transacted with an international pharmaceutical company," says Chairman of the Board of Directors, Dr Magnus Persson. "We are very confident that Hilde will be an inspiring and highly effective leader as we build on our deal with Otsuka to create value for all our stakeholders. We wish to thank Damian Marron for his highly productive leadership as Interim CEO during the last few months and look forward to continuing working with him in his capacity as independent director."","length":689,"tagName":"p"},{"type":"text","content":"Dr Hilde S...